* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Figure 14-10 - University of Belgrade
Survey
Document related concepts
Herd immunity wikipedia , lookup
Anti-nuclear antibody wikipedia , lookup
Hygiene hypothesis wikipedia , lookup
Lymphopoiesis wikipedia , lookup
DNA vaccination wikipedia , lookup
Social immunity wikipedia , lookup
Molecular mimicry wikipedia , lookup
Monoclonal antibody wikipedia , lookup
Immune system wikipedia , lookup
Immunocontraception wikipedia , lookup
Polyclonal B cell response wikipedia , lookup
Adaptive immune system wikipedia , lookup
Innate immune system wikipedia , lookup
Psychoneuroimmunology wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
Transcript
Tumor immunology Content IMMUNOLOGICAL SURVEILLANCE TUMOR ANTIGENS EFFECTOR MECHANISMS IN ANTITUMOR IMMUNITY MECHANISMS OF EVASION OF THE IMMUNE SYSTEM BY TUMORS TUMOR IMMUNOTHERAPY Immunosurveillance Physiological function of the immune system to recognize and destroy malignantly transformed cells before they grow into tumors, or to kill tumors after they are formed Tumor antigens • Tumor-specific antigens (TSA) Antigens expressed on tumor cells but not on normal cells • Tumor-associated antigens (TAA) Antigens expressed concurently on normal cells Figure 14-12 Figure 14-12 Figure 14-13 Effector mechanisms in anti-tumor immunity T lymphocytes NK cells Antibodies Macrophages Effector mechanisms in anti-tumor immunity T lymphocytes NK cells Antibodies Macrophages Figure 1-6 Figure 9-34 part 1 of 2 Figure 9-34 part 2 of 2 Effector mechanisms in anti-tumor immunity T lymphocytes NK cells Antibodies Macrophages Effector mechanisms in anti-tumor immunity T lymphocytes NK cells Antibodies Macrophages Mechanisms of evasion of the immune response by tumors IMPORTANT ISSUES IN DESIGNING EFFECTIVE CANCER VACCINE Too less good things for initiation of antitumor immune response Failure to produce and/or present antigen Failure to activate T cells Too many bad things for maintenance of an effective antitumor immune response Immunosuppresive cytokines Induction of immunoprivileges Induction of regulatory cells Figure 14-14 part 1 of 2 Figure 14-14 part 2 of 2 Tumor immunotherapy Nonspecific Specific Passive Monoclonal Abs adoptive (LAK, TIL) Active Vaccination Figure 14-17 IMPORTANT ISSUES IN DESIGNING EFFECTIVE CANCER VACCINE To identify potent tumor rejection antigens To stimulate an effective antitumor immune response To avoid autoimmune pathology